The Christie Hospital Tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma - 7-yr results

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

“…This study suggests that male patients with breast cancer have a much higher incidence of side effects with resulting attrition from adjuvant tamoxifen treatment (25 YO) than that reported for their female counterparts who received the same treatment (4%), 13,14 We found that five (20.8%) patients stopped their tamoxifen treatment in less than 1 year.…”

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

“…This study suggests that male patients with breast cancer have a much higher incidence of side effects with resulting attrition from adjuvant tamoxifen treatment (25 YO) than that reported for their female counterparts who received the same treatment (4%), 13,14 We found that five (20.8%) patients stopped their tamoxifen treatment in less than 1 year.…”

Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF+ tamoxifen in a single centre

“…As already published, patients over 50 years obtain a better result than the younger ones under CMF + Tam [6,14,17]. As in the ECOG premenopausal trial, tamoxifen does not improve RFS and OS in young patients [21].…”

The Christie hospital adjuvant tamoxifen trial – status at 10 years

“…The primary objective was to find out if tamoxifen (TAM) when prescribed for a period of one year following surgery would prolong overall and/or disease free survival in pre-and postmenopausal patients. All the patients were treated at the Christie Hospital and Holt Radium Institute, Manchester.The seven year results have been previously published (Ribeiro & Swindell, 1985). The present paper presents the ten year status.…”

“…The seven year results have been previously published (Ribeiro & Swindell, 1985). The present paper presents the ten year status.…”

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

“…This study suggests that male patients with breast cancer have a much higher incidence of side effects with resulting attrition from adjuvant tamoxifen treatment (25 YO) than that reported for their female counterparts who received the same treatment (4%), 13,14 We found that five (20.8%) patients stopped their tamoxifen treatment in less than 1 year.…”

Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF+ tamoxifen in a single centre

“…As already published, patients over 50 years obtain a better result than the younger ones under CMF + Tam [6,14,17]. As in the ECOG premenopausal trial, tamoxifen does not improve RFS and OS in young patients [21].…”

The Christie hospital adjuvant tamoxifen trial – status at 10 years

“…The primary objective was to find out if tamoxifen (TAM) when prescribed for a period of one year following surgery would prolong overall and/or disease free survival in pre-and postmenopausal patients. All the patients were treated at the Christie Hospital and Holt Radium Institute, Manchester.The seven year results have been previously published (Ribeiro & Swindell, 1985). The present paper presents the ten year status.…”

“…The seven year results have been previously published (Ribeiro & Swindell, 1985). The present paper presents the ten year status.…”

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

“…This study suggests that male patients with breast cancer have a much higher incidence of side effects with resulting attrition from adjuvant tamoxifen treatment (25 YO) than that reported for their female counterparts who received the same treatment (4%), 13,14 We found that five (20.8%) patients stopped their tamoxifen treatment in less than 1 year.…”

Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF+ tamoxifen in a single centre

“…As already published, patients over 50 years obtain a better result than the younger ones under CMF + Tam [6,14,17]. As in the ECOG premenopausal trial, tamoxifen does not improve RFS and OS in young patients [21].…”

The Christie hospital adjuvant tamoxifen trial – status at 10 years

“…The primary objective was to find out if tamoxifen (TAM) when prescribed for a period of one year following surgery would prolong overall and/or disease free survival in pre-and postmenopausal patients. All the patients were treated at the Christie Hospital and Holt Radium Institute, Manchester.The seven year results have been previously published (Ribeiro & Swindell, 1985). The present paper presents the ten year status.…”

“…The seven year results have been previously published (Ribeiro & Swindell, 1985). The present paper presents the ten year status.…”